Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Micaela B. Reddy is active.

Publication


Featured researches published by Micaela B. Reddy.


Pharmaceutical Research | 2002

Determining dermal absorption parameters in vivo from tape strip data

Micaela B. Reddy; Audra L. Stinchcomb; Richard H. Guy; Annette L. Bunge

AbstractPurpose: Tape stripping the outermost skin layer, the stratum corneum (sc), is a popular method for assessing the rate and extent of dermal absorption in vivo. Results from tape strip (TS) experiments can be affected significantly by chemical diffusion into the sc during the time required to apply and remove all of the TSs, tTS. Here, we examine the effects of this problem on the interpretation of TS experimental results. Methods: Dermal absorption of 4-cyanophenol (4CP) in humans was studied using TS experiments to assess conditions in which diffusion alters TS results. Mathematical models were developed to assess the effects of diffusion on parameter estimation. Results: For an experiment with tTS > tlag (i.e., the lag time for a chemical to cross the sc), the permeability coefficient for 4CP, Psc,v, calculated including tTS, was consistent with values from the literature (i.e., 0.0019 cm/h). When diffusion during stripping was not included in the model, Psc,v was 70% smaller. Conclusions: Calculations show that chemical concentrations in TSs can be affected by diffusion during tape stripping, but if tTS < 0.2 tlag and the exposure time is > 0.3 tlag, TS concentrations are not significantly affected by tTS.


Pharmaceutical Research | 2000

Does Epidermal Turnover Reduce Percutaneous Penetration

Micaela B. Reddy; Richard H. Guy; Annette L. Bunge

AbstractPurpose. After its removal from the skin surface, chemical remaining within the skin can become systemically available. The fraction of chemical in the skin that eventually enters the body depends on the relative rates of percutaneous transport and epidermal turnover (i.e., stratum corneum desquamation). Indeed, some investigators have claimed that desquamation is an efficient mechanism for eliminating dermally absorbed chemical from the skin. Methods. The fate of chemical within the skin following chemical contact was examined using a mathematical model representing turnover of and absorption into the stratum corneum and viable epidermis. The effects of turnover rate, exposure duration, penetrant lipophilicity, and lag time for chemical diffusion were explored. Results. These calculations show that significant amounts of chemical can be removed from skin by desquamation if epidermal turnover is fast relative to chemical diffusion through the stratum corneum. However, except for highly lipophilic and/or high molecular weight (>350 Da) chemicals, the normal epidermal turnover rate is not fast enough and most of the chemical in the skin at the end of an exposure will enter the body. Conclusions. Epidermal turnover can significantly reduce subsequent chemical absorption into the systemic circulation only for highly lipophilic or high molecular weight chemicals.


Toxicological Sciences | 2008

Inhalation Dosimetry Modeling with Decamethylcyclopentasiloxane in Rats and Humans

Micaela B. Reddy; Ivan D. Dobrev; Debra A. McNett; Joseph M. Tobin; Mark J. Utell; Paul E. Morrow; Jeanne Y. Domoradzki; Kathleen P. Plotzke; Melvin E. Andersen

Decamethylcyclopentasiloxane (D(5)), a volatile cyclic methyl siloxane (VCMS), is used in industrial and consumer products. Inhalation pharmacokinetics of another VCMS, octamethylcyclotetrasiloxane (D(4)), have been extensively investigated and successfully modeled with a multispecies physiologically based pharmacokinetic (PBPK) model. Here, we develop an inhalation PBPK description for D(5), using the D(4) model structure as a starting point, with the objective of understanding factors that regulate free blood and tissue concentrations of this highly lipophilic vapor after inhalation in rats and humans. Compared with D(4), the more lipophilic D(5) required deep compartments in lung, liver, and plasma to account for slow release from tissues after cessation of exposures. Simulations of the kinetics of a stable D(5) metabolite, HO-D(5), required diffusion-limited uptake in fat, a deep tissue store in lung, and its elimination by fecal excretion and metabolism to linear silanols. The combined D(5)/HO-D(5) model described blood and tissue concentrations of parent D(5) and elimination of total radioactivity in single and repeat exposures in male and female rats at 7 and 160 ppm. In humans, D(5) kinetic data are more sparse and the model structure though much simplified, still required free and bound blood D(5) to simulate exhaled air and blood time courses from 1 h inhalation exposures at 10 ppm in five human volunteers. This multispecies PBPK model for D(5) highlights complications in interpreting kinetic studies where chemical in blood and tissues represents various pools with only a portion free. The ability to simulate free concentrations is essential for dosimetry based risk assessments for these VCMS.


Toxicology Letters | 2008

Are highly lipophilic volatile compounds expected to bioaccumulate with repeated exposures

Melvin E. Andersen; Micaela B. Reddy; Kathleen P. Plotzke

With non-volatile compounds, high lipophilicity (i.e., fat:blood partition coefficients, Pf, in the range of several hundred to a thousand or higher) typically leads to concerns for bioaccumulation. To evaluate the extent to which highly cleared, lipophilic vapors are expected to accumulate in blood and tissues, we conducted pharmacokinetic (PK) analysis, using both a generic physiologically based (PBPK) model for inhalation of volatile compounds (VCs) and a more detailed PBPK model specifically developed for a highly lipophilic volatile (decamethylcyclopentasiloxane, D(5)). The generic PBPK model for inhalation of VCs in humans showed that highly metabolized, lipophilic compounds, with a low blood:air partition coefficient (Pb), do not accumulate in blood or systemic tissues with repeat exposures although a period of days to weeks may be required for fat to reach periodic steady state. VCs with higher Pb (in the hundreds) and lower hepatic extraction accumulate in blood on repeat exposures. The more detailed PBPK model for D(5) also showed that this lipophilc VC does not accumulate in blood and predictions of the increases in D(5) in fat with repeat exposures in rats agreed with experiments. In general, the major characteristic favoring accumulation of VCs in blood and systemic tissues is poor whole-body clearance, not lipophilicty. The term bioaccumulation should be used to refer to cases where repeat exposures lead to increases in VC blood (or central compartment) concentration. Based on this definition, highly cleared VCs, such as D(5), would not be considered to bioaccumulate on repeat exposures.


Inhalation Toxicology | 2003

Closed-Chamber Inhalation Pharmacokinetic Studies with Hexamethyldisiloxane in the Rat

Ivan D. Dobrev; Micaela B. Reddy; Kathleen P. Plotzke; Sudarsanan Varaprath; Debra A. McNett; Jeremy Durham; Melvin E. Andersen

Gas uptake methods together with physiologically based pharmacokinetic (PBPK) modeling have been used to assess metabolic parameters and oral absorption rates for a wide variety of volatile organic compounds. We applied these techniques to study the in vivo metabolism of hexamethyldisiloxane (HMDS), a volatile siloxane with low blood/air (partition coefficient PB ≈ 1.00) and high fat/blood partitioning (partition coefficient PF ≈ 300). In contrast to other classes of metabolized volatiles, metabolic parameters could only be estimated from closed-chamber results with confidence by evaluating both closed-chamber disappearance curves and constant concentration inhalation studies. The constant-concentration inhalation results refine the estimate of the blood/air partition coefficient and constrain model structure for storage of the lipophilic compound in blood and tissues. The gas uptake results, from Fischer 344 rats (male, 8-9 wk old) exposed to initial HMDS air concentrations from 500 to 5000 ppm, were modeled with a 5-tissue PBPK model. Excellent fits were obtained with diffusion-limited uptake of HMDS in fat and a lipid storage pool in the blood. Metabolism, restricted to the liver, was described as a single saturable process (V max = 113.6 µmol/h/kg; K m = 42.6 µmol/L) and was affected by inhibitors (diethyldithiocarbamate) or inducers (phenobarbital) of cytochrome P-450s. Exhalation kinetics of HMDS after oral/intraperitoneal administration showed low bioavailability and significant lag times, also quite different from results of other classes of volatile hydrocarbons. In general, estimates of metabolic clearance by gas uptake studies were improved by simultaneous examination of time-course results from constant concentration inhalation studies. This conclusion is likely to hold for any volatile lipophilic compound with low blood/air partitioning.


Inhalation Toxicology | 2008

Assessing Kinetic Determinants for Metabolism and Oral Uptake of Octamethylcyclotetrasiloxane (D4) from Inhalation Chamber Studies

Ivan D. Dobrev; Andy Nong; Kai H. Liao; Micaela B. Reddy; Kathleen P. Plotzke; Melvin E. Andersen

The pharmacokinetics of octamethylcyclotetrasiloxane (D4), a highly lipophilic and well-metabolized volatile cyclic siloxane, are more complex than those of other volatile hydrocarbons. The purpose of the present study was to evaluate rate constants for saturable metabolism in the body, to estimate possible presystemic D4 clearance by respiratory-tract tissues, and to assess rate constants for uptake of D4 after oral dosing. These experiments provided the opportunity to refine current physiologically based pharmacokinetic (PBPK) models for D4 and to independently estimate key model parameters by sensitive inhalation methods. The PBPK model could only be fitted to gas uptake results when metabolic capacity was included in the respiratory-tract epithelium. The model simulations were highly sensitive to the parameter for total percent of whole-body metabolism allocated to the respiratory tract, with optimal fits observed with this value equal to 5%. Oral uptake of D4 was evaluated using both closed and open chamber concentration time-course studies after intubation of D4 in corn oil. Conclusions from the oral uptake studies were also verified by comparison with independent data sets for blood concentrations of D4 after oral dosing. The pharmacokinetic (PK) analysis of uptake from the gut and release from blood into chamber air results for oral doses from 10 to 300 mg D4/kg body weight were consistent with a combination of prolonged and slow uptake of D4 from the gastrointestinal tract and of reduced absorption at higher doses, as well as the extrahepatic clearance of D4 in pulmonary tissues. These closed chamber gas uptake studies provide a valuable confirmation of the conclusions reached in other pharmacokinetic studies and have uncovered a situation where closed chamber loss is highly sensitive to respiratory-tract clearance. This sensitivity largely arises from the unusual characteristics of D4: high-affinity metabolic clearance and low blood:air partitioning.


Archives of Toxicology | 2008

Quantitative analysis of liver GST-P foci promoted by a chemical mixture of hexachlorobenzene and PCB 126: implication of size-dependent cellular growth kinetics

Yasong Lu; Manupat Lohitnavy; Micaela B. Reddy; Ornrat Lohitnavy; Elizabeth Eickman; Amanda K. Ashley; Lisa Gerjevic; Yihua Xu; Rory B. Conolly; Raymond S. H. Yang

The objectives of this study were twofold: (1) evaluating the carcinogenic potential of the mixture of two persistent environmental pollutants, hexachlorobenzene (HCB) and 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126), in an initiation-promotion bioassay involving the development of π glutathione S-transferase (GST-P) liver foci, and (2) analyzing the GST-P foci data using a biologically-based computer model (i.e., clonal growth model) with an emphasis on the effect of focal size on the growth kinetics of initiated cells. The 8-week bioassay involved a series of treatments of initiator, two-thirds partial hepatectomy, and daily oral gavage of the mixture of two doses in male F344 rats. The mixture treatment significantly increased liver GST-P foci development, indicating carcinogenic potential of this mixture. Our clonal growth model was developed to simulate the appearance and development of initiated GST-P cells in the liver over time. In the model, the initiated cells were partitioned into two subpopulations with the same division rate but different death rates. Each subpopulation was further categorized into single cells, mini- (2–11 cells), medium- (12–399 cells), and large-foci (>399 cells) with different growth kinetics. Our modeling suggested that the growth of GST-P foci is size-dependent; in general, the larger the foci, the higher the rate constants of division and death. In addition, the modeling implied that the two doses promoted foci development in different manners even though the experimental foci data appeared to be similar between the two doses. This study further illustrated how clonal growth modeling may facilitate our understanding in chemical carcinogenic process.


Archive | 2013

Physiologically Based Pharmacokinetic Modeling: A Tool for Understanding ADMET Properties and Extrapolating to Human

Micaela B. Reddy; Harvey J. Clewell; Thierry Lavé; Melvin E. Andersen

Physiologically based pharmacokinetic (PBPK) models differ from classical PK models in that they include specific compartments for tissues involved in exposure, toxicity, biotransforma‐ tion and clearance processes connected by blood flow (Figure 1). Compartments and blood flows are described using physiologically meaningful parameters, which allows for interspe‐ cies extrapolation by altering the physiological parameters appropriately [1]. A key benefit to PBPK models is that factors influencing the absorption, distribution, metabolism, and elimi‐ nation of a compound can be incorporated into a PBPK model in a mechanistic, meaningful way, if a mechanism is understood and sufficient data are available. This mechanistic aspect is supported by physiological parameters influencing absorption (e.g., pH values and transit times through various sections of the GI tract), distribution (e.g., tissue volumes and compo‐ sition), metabolism (e.g., expression levels of various hepatic enzymes and transporters involved with metabolic elimination), and elimination (e.g., glomerular filtration rate and expression levels of transporters in the kidneys involved with renal elimination), which can be explicitly incorporated in the PBPK model.


Archive | 2002

Dermal Absorption from Pesticide Residues

Micaela B. Reddy; Annette L. Bunge

In its regulatory role the United States Environmental Protection Agency is the repository for a large collection of dermal absorption data supplied by pesticide registrants. Many of these studies followed a common procedure measuring dermal absorption in vivo into laboratory rats as a function of both the amount of pesticide applied and the exposure time. In this chapter, example registrant data are presented and analyzed. For the 18 pesticides examined in this study, the relationship between systemic absorption and applied dose was different for pesticides that are liquids and those that are solids at skin temperature. For both groups, the amount of pesticide in skin increased proportionally with applied dose. Systemic absorption of liquid pesticides also increased with applied dose. However, for solid pesticides systemic absorption was a weaker function of applied dose and in some cases was independent of applied dose. Finally, a simple method for estimating the maximum systemic absorption using a pesticide’s permeability coefficient and water solubility under-estimated the amount of dermal absorption for most doses of many of the pesticides investigated in this study.


Archive | 2005

Physiologically based pharmacokinetic modeling : science and applications

Micaela B. Reddy; Raymond S. H. Yang; Harvey J. Clewell; Melvin E. Andersen

Collaboration


Dive into the Micaela B. Reddy's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ivan D. Dobrev

Colorado State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amanda K. Ashley

New Mexico State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael M. Reddy

United States Geological Survey

View shared research outputs
Researchain Logo
Decentralizing Knowledge